Obesity therapy update presenting clinical and preclinical data from a biotech testing a novel metabolic combination, with context and implications.
Key Takeaways
- 24-week Phase 2a trial tested a mitochondrial protonophore alongside tirzepatide in obesity
- Preclinical TLC-1180 improved insulin sensitivity across liver, muscle, heart, and adipose tissues
- Treated animals showed better exercise performance and partial cognitive restoration in obesity models